The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).

##STR00001##

Sodium, piperazine, and hydrochloride salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (Compound 1) are provided herein.

Provided is an process for the automated synthesis of at least one chemical compound including providing at least one substrate in at least one solvent in the at least one reaction container; automatically passing the at least one substrate through at least one first compartment of the at least one cartridge once or several times and collecting a formed substrate-reagent intermediate product in the at least one reaction container prior to passing the substrate-reagent intermediate product into a subsequent compartment; automatically passing the substrate-reagent intermediate product through at least one second compartment once or several times and collecting a formed reaction product prior to passing the reaction product into a subsequent compartment; automatically passing the reaction product through at least one third compartment for purifying the product once or several times and collecting a purified product in the at least one reaction container.

Provided is an process for the automated synthesis of at least one chemical compound including providing at least one substrate in at least one solvent in the at least one reaction container; automatically passing the at least one substrate through at least one first compartment of the at least one cartridge once or several times and collecting a formed substrate-reagent intermediate product in the at least one reaction container prior to passing the substrate-reagent intermediate product into a subsequent compartment; automatically passing the substrate-reagent intermediate product through at least one second compartment once or several times and collecting a formed reaction product prior to passing the reaction product into a subsequent compartment; automatically passing the reaction product through at least one third compartment for purifying the product once or several times and collecting a purified product in the at least one reaction container.